Skip to main content
NewslettersWatchlist

Grifols S.A. ADR(GRFS-Q)
NASDAQ

Today's Change
Real-Time Last Update Last Sale Cboe BZX Real-Time
Day Low8.18
Day High8.59
Open:8.44
Price movement based on the high, low and last over the given period.
Previous Close
52-Week High/Low
Volume
Average Volume
Price/Earnings (TTM)
Forward Annual Dividend & Yield
Market Capitalization, $M
5-Day Change
Realtime quote and/or trade prices are not sourced from all markets.
Select a category then submit the form to load news
TheNewswire.com
INVESTIGATION ALERT: Grifols SA Faces Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
TheNewswire.com
Grifols SA is Being Investigated for Potential Securities Law Violations - Contact Kaplan Fox & Kilsheimer LLP
TheNewswire.com
Grifols SA Investors are Encouraged to Contact Kaplan Fox & Kilsheimer LLP Regarding Potential Securities Law Violations
TheNewswire.com
GRFS Is Being Investigated for Potential Securities Law Violations Contact Kaplan Fox & Kilsheimer LLP
TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Possible Securities Law Violations against Grifols SA (GRFS)
TheNewswire.com
Kaplan Fox & Kilsheimer LLP is Investigating Grifols SA (GRFS) for Potential Securities Law Violations
TheNewswire.com
Grifols, S.A. (NASDAQ: GRFS) Short Seller Report: Kaplan Fox Investigates Grifols, S.A.
TheNewswire.com
Grifols, S.A. (NASDAQ: GRFS) Shareholder Alert: Kaplan Fox Investigates Claims on Behalf of Grifols, S.A. Investors
TheNewswire.com
Grifols, S.A. (NASDAQ: GRFS) Investor Alert: Kaplan Fox & Kilsheimer LLP Investigates Grifols, S.A. for Potential Securities Violations
TheNewswire.com
Kaplan Fox & Kilsheimer LLP Investigates Grifols, S.A. (Nasdaq: GRFS)
The Globe and Mail
The Globe’s stars and dogs for the week
PR Newswire
DelveInsight Evaluates a Robust Dry Eye Disease Clinical Trial Pipeline as 60+ Influential Pharma Players to Set Foot in the Domain
Motley Fool
Why Shares of Grifols Were Up Tuesday
PR Newswire
Grifols 2022 Annual Report on Form 20-F filed with the SEC on April 18, 2023
PR Newswire
Selagine Enters into a Collaborative Agreement with Grifols for Development and Commercialization of Immunoglobulin Eye Drops for Treating Dry Eye Disease
PR Newswire
Victor Grifols Roura decides to retire as Chairperson; Grifols appoints private equity veteran Steven F. Mayer as Executive Chairperson
PR Newswire
Grifols enters into agreement with Canadian Blood Services to accelerate self-sufficiency in immunoglobulins for Canada
Motley Fool
Got $20? These 3 Healthcare Stocks Could Be Bargain Buys for 2022 and Beyond
Business Wire
Illumina Ventures Announces Promotion and Additions to its Investment Team
PR Newswire
Grifols and Egypt inaugurate first African plasma-supply platform, in Cairo, as part of the alliance to attain self-sufficiency in plasma-derived medicines
Globe NewsWire
GigaGen Licenses ProteoNic’s 2G UNicTM Technology Platform for High Yield Production of GigaGen’s Mono- and Polyclonal Antibody Drug Candidates
Globe NewsWire
GigaGen Doses First Patient in Phase 1 Trial of Recombinant Hyperimmune Polyclonal Antibody GIGA-2050 for COVID-19

Profile

Grifols, S.A., operates in the pharmaceutical-hospital sector engaged in the research, development and retailing of plasma derivates, products for intravenous therapy, clinical nutrition, diagnostic and hospital logistics systems. The Company operates its business through three divisions: Bioscience Division, Diagnostic Division and Hospital Division. The Bioscience division is engaged in the research, development, production and commercialization of plasma derivates. Diagnostic Division focuses on researching, developing, manufacturing and marketing diagnostics products for laboratory analysis, including products for Hospital Blood Banks and Transfusion Centers. Hospital Division provides non-biological products used in hospital pharmacies, surgery, nutritional support, fluid therapy and for other therapeutic uses. Grifols, S.A. is based in Barcelona, Spain.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2024.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).

Copyright © 2024 Morningstar. All Rights Reserved. The information contained herein: (1) is proprietary to Morningstar and/or its content providers; (2) may not be copied or distributed; and (3) is not warranted to be accurate, complete or timely. Neither Morningstar nor its content providers are responsible for any damages or losses arising from any use of this information. Past performance is no guarantee of future results.